Application of BAMBI as nasopharyngeal carcinoma maker

Abstract

The invention discloses an application of BAMBI as a nasopharyngeal carcinoma maker. Through experiment researches by an applicant and a whole team for three years, researches on tissues and serums of 38 nasopharyngeal carcinoma patients, 12 chronic nasopharyngitis patients and 49 healthy volunteers are carried out, the researches show that the nasopharyngeal tissue BAMBI expression amount of the nasopharyngeal carcinoma patients is obviously increased, the expression amount of nasopharyngitis (nasopharyngitis is common benign disease) is relatively low, wherein p equals 0.0038, and the difference between nasopharyngeal carcinoma and nasopharyngitis is obvious. The serum BAMBI of the nasopharyngeal carcinoma patients is obviously increased, through statistical analysis, t equals 2.639, and p equals 0.012. No matter in nasopharyngeal carcinoma tissue or nasopharyngeal carcinoma serum, BAMBI presents up-regulated expression, so that the detection of BAMBI can be taken as a nasopharyngeal carcinoma molecular screening index.

Description

technical field [0001] The invention belongs to the detection field, and in particular relates to the application of BAMBI as a nasopharyngeal carcinoma marker. Background technique [0002] The transmembrane inhibitor (BMP and activin membrane—boundinhibitor, BAMBI) of bone morphogenic protein and activin is a kind of transmembrane glycoprotein, and BAMBI gene is by Onichtchouk etc. (Onichtchouk D, Chen YG, Dosch R, el a1.Silencing of TGF-beta signaling by the pseudoreceptor BAMBI.Nature, 1999, 401(6752): 480-485) was discovered in 1999, located in the p12.3-pl1.2 region of chromosome 10, and the encoded product is a 260-amino acid It is a transmembrane glycoprotein with a molecular weight of 29108kD, also known as a pseudoreceptor (Pseudoreceptor), which is compatible with the extracellular domains of type I receptors of ligands such as bone morphogenetic protein (BMP) and activin (activin). With a similar structure, BAMBI competes with TGF-β type I receptors for ligand b...

AI Technical Summary

Problems solved by technology

Other molecular markers identified as nasopharyngeal carcinoma are rarely used in clinical applications

Images